348 related articles for article (PubMed ID: 25986251)
21. Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures.
Lee DJ; Barocas DA; Zhao Z; Huang LC; Koyama T; Resnick MJ; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
Pract Radiat Oncol; 2018; 8(5):307-316. PubMed ID: 30177030
[TBL] [Abstract][Full Text] [Related]
22. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
23. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
Roach M
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
[TBL] [Abstract][Full Text] [Related]
24. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
25. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
[TBL] [Abstract][Full Text] [Related]
26. Practice patterns in the management of prostate cancer in Spain: results from a national survey among radiation oncologists in 2009.
Zapatero A; López-Torrecilla J; Herruzo I; Calvo FA;
Clin Transl Oncol; 2013 Mar; 15(3):226-32. PubMed ID: 22855195
[TBL] [Abstract][Full Text] [Related]
27. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice.
Panje C; Zilli T; Dal Pra A; Arnold W; Brouwer K; Garcia Schüler HI; Gomez S; Herrera F; Khanfir K; Papachristofilou A; Pesce G; Reuter C; Vees H; Zwahlen D; Putora PM
Radiat Oncol; 2019 Oct; 14(1):177. PubMed ID: 31619296
[TBL] [Abstract][Full Text] [Related]
28. PROLAPSE: survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Zerini D; Jereczek-Fossa BA; Ciabattoni A; Mirri A; Bertoni F; Fersino S; D'Agostino G; Lohr F; Mortellaro G; Triggiani L; Marvaso G; Pepa M; Cuccia F; Alongi F;
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2311-2317. PubMed ID: 32583236
[TBL] [Abstract][Full Text] [Related]
29. Radiotherapy and Hormone Treatment in Prostate Cancer.
Böhmer D; Wirth M; Miller K; Budach V; Heidenreich A; Wiegel T
Dtsch Arztebl Int; 2016 Apr; 113(14):235-41. PubMed ID: 27146591
[TBL] [Abstract][Full Text] [Related]
30. Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy.
Vainshtein JM; Schipper M; Vance S; Feng FY; Olson KB; Hamstra DA
Am J Clin Oncol; 2016 Apr; 39(2):173-80. PubMed ID: 24487421
[TBL] [Abstract][Full Text] [Related]
31. Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.
Kasuya G; Ishikawa H; Tsuji H; Nomiya T; Makishima H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Haruyama Y; Kobashi G; Tsujii H;
Cancer; 2016 Oct; 122(20):3225-3231. PubMed ID: 27351298
[TBL] [Abstract][Full Text] [Related]
32. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
33. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
Makino T; Mizokami A; Namiki M
Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
[TBL] [Abstract][Full Text] [Related]
35. Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study.
Rijksen BLT; Pos FJ; Hulshof MCCM; Vernooij RWM; Jansen H; van Andel G; Wijsman BP; Somford DM; Busstra MB; van Moorselaar RJA; Kaa CAH; van Leenders GJLH; Hamberg P; van den Berkmortel F; Fütterer JJ; Kiemeney LA; van Oort IM; Aben KKH
Eur Urol Focus; 2021 Mar; 7(2):332-339. PubMed ID: 31748122
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
[TBL] [Abstract][Full Text] [Related]
37. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
[TBL] [Abstract][Full Text] [Related]
38. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
39. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
[TBL] [Abstract][Full Text] [Related]
40. Dramatically Polarized Opinion on the Role of Brachytherapy Boost in Management of High-risk Prostate Cancer: A Survey of North American Genitourinary Expert Radiation Oncologists.
McClelland S; Sandler KA; Degnin C; Chen Y; Mitin T
Clin Genitourin Cancer; 2018 Jun; 16(3):e543-e545. PubMed ID: 29452837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
